Medifast (MED) Cost of Revenue (2010 - 2026)

Medifast (MED) has 17 years of Cost of Revenue data on file, last reported at $24.3 million in Q1 2026.

• Quarterly Cost of Revenue fell 22.85% year-over-year to $24.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.4 million (down 27.12% YoY) and the FY2025 annual result came in at $110.6 million, down 29.93% from the prior year.
• Cost of Revenue advanced to $24.3 million in Q1 2026, from $23.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $131.7 million in Q2 2022 to a low of $23.0 million in Q4 2025.
• A 5-year average of $61.6 million and a median of $47.4 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue surged 31.02% — and 2024, when it sank 53.75%.
• Tracing MED's Cost of Revenue over 5 years: stood at $103.6 million in 2022, then slumped by 52.1% to $49.6 million in 2023, then slumped by 37.99% to $30.8 million in 2024, then decreased by 25.43% to $23.0 million in 2025, then advanced by 5.8% to $24.3 million in 2026.
• The last three Cost of Revenue figures came in at $24.3 million (Q1 2026), $23.0 million (Q4 2025), and $27.2 million (Q3 2025), per Business Quant data.